How to Write a Biotechnology Advances Cover Letter (With Template)

Source: Biotechnology Advances guide for authors, Elsevier cover letter guidance (accessed June 2026)

The order matters. Editors at a review journal are scanning for argument density, not literary polish. A letter that names the new synthesis, justifies the timing, and confirms applied fit in that sequence is easy to route. A letter that opens with how much literature you have read is easy to desk-reject.

Elsevier requires confirmation that the work is original and not under review elsewhere, and that all authors approved the submission. State it verbatim in the letter even though the Editorial Manager forms also capture parts of it:

This manuscript is original, has not been published previously, and is not under consideration for publication elsewhere. All authors have read and approved the submission and agree to its publication in Biotechnology Advances.

For a review, add one extra line that primary-data submissions do not need: confirm the synthesis is your own and that figures are original schematics rather than reused conceptual diagrams from earlier reviews. Editors at Biotechnology Advances watch for recycled review figures, so a one-sentence originality note on the schematics is worth including.

The opener is the single most diagnostic line in the letter. For a review journal it must promise synthesis, not coverage.

A weak opener describes coverage, so avoid it:

A stronger opener takes a position, so use one instead.

Weak opener:

"We present a comprehensive review covering recent advances in microbial bioprocessing over the past decade."

Why it fails:

• "comprehensive" signals a survey, not a position
• no contested question
• no reason the field needs this review now
• no applied biotechnology decision

Strong opener:

"We argue that continuous, rather than fed-batch, fermentation is the only scalable route to economically viable production of [target molecule], and we resolve the contradictory yield data across the last five years to show exactly where the scale-up bottleneck sits."

Why it works:

• it takes a defensible position the reader can disagree with
• it names a specific industrial decision
• it explains why the review matters now (conflicting recent data)
• it reads like applied biotechnology, not basic biology

Biotechnology Advances accepts more than one article type, and the cover letter should name yours explicitly because the editorial bar differs by type.

If you are submitting a Review, do not borrow primary-data novelty language. The editor is not asking "is this result new?" but "is this synthesis new and does it change a decision?" Naming the article type in the first sentence tells the editor which bar to apply and prevents a scope misread at triage.

Elsevier separates declarations and reviewer suggestions from the cover letter body and collects them as their own steps in Editorial Manager. Do not duplicate the forms, but get them right because a clean submission package reinforces the impression of careful work.

• Suggested reviewers. Provide 2 to 4 reviewers spanning academic biotechnology, industrial bioprocess, and where relevant regulatory expertise. Exclude reviewers who are recent collaborators, co-authors from the past several years, or institutional colleagues, since the editor will discount obvious conflicts. The single anonymized screen means the suggested reviewers may be the ones who see the work, so credibility matters more than convenience.

• Declaration of competing interest. Complete the declarations tool even when there is nothing to declare.

A blank declaration reads as an oversight at triage.

• Funding statement. List funders and grant numbers, or state that the work received no specific funding.

• Data availability statement. Required for every submission. For a review, state where any reanalyzed data or supplementary datasets reside.

You may reference these briefly in the letter ("we have suggested four reviewers across academic and industrial biotechnology and completed all declarations"), but the forms are the source of truth.

When we read a Biotechnology Advances cover letter the way an editor would, the first ten seconds decide whether the manuscript is a review or a survey. We scan the opening sentence for a position. If the letter says the review will "cover" or "summarize" a field, the editorial path bends toward a desk return, because the journal already has reviews that summarize.

If the letter says the review "argues," "resolves," or "shows that one approach beats another," we keep reading, because that is the synthesis the journal exists to publish. The cover letter is where the editor decides which kind of manuscript you sent, and a precise opener is the cheapest way to be read as the right kind.

In our pre-submission review work with Biotechnology Advances submissions, the cover letter fails in three patterns that consistently predict a desk return before the manuscript file is opened.

The comprehensiveness pitch. The most common pattern is a cover letter that promises to "comprehensively cover" or "provide an overview of" recent advances. Across our Biotechnology Advances reviews, this framing is the single strongest desk-rejection predictor, because it tells the editor the review describes the field rather than taking a position on it. The fix lives in one sentence: replace coverage language with a defensible claim about which approach is industrially or therapeutically viable.

When authors rewrite the opener from "we review recent progress in X" to "we argue that X-approach-A outperforms X-approach-B for scale-up and explain why," the same manuscript reads as a Review rather than a survey.

The missing why-a-review-now argument. A second pattern we see in Biotechnology Advances cover letters is a letter that never justifies the timing. Authors assume the editor will infer urgency from the topic's popularity. Editors do not. The letter has to name a concrete trigger: a new platform that changed the cost structure, a scale-up bottleneck that recent studies disagree about, or contradictory yield or efficacy data that a critical synthesis can resolve.

A review without a timing argument competes poorly against submissions that explain exactly why the field needs this synthesis this year.

The application-pathway claim that the synthesis never demonstrates. The third pattern ties the cover letter back to a manuscript component the editor will check: the application-pathway block and the figures. Authors name an industrial or therapeutic application in the cover letter and the title, but the body and the synthesis schematics never argue the deployment logic.

When the figures are reused conceptual diagrams rather than original synthesis schematics, the gap between the letter's promise and the manuscript's delivery becomes obvious at triage. We flag this when the cover letter's application claim has no matching argument in the synthesis, because a Biotechnology Advances editor reads the applied payoff as the reason the review belongs here rather than in a more discursive trends-style venue.

These are testable before you submit. A Biotechnology Advances synthesis and desk-reject risk check evaluates whether your cover letter's synthesis claim is actually argued in the manuscript and whether the applied-fit framing holds, usually in a couple of minutes.

If you cannot write a synthesis-position sentence without sliding back into coverage language, that is useful information. It may mean the manuscript really is a literature survey, which fits a more topical venue like Current Opinion in Biotechnology better than Biotechnology Advances. If the strongest version of your applied-fit argument still depends on the reader assuming a deployment path you never demonstrate, the review may not yet be ready for this journal.

How this page was created: this guide draws on the Biotechnology Advances guide for authors, Elsevier's public cover-letter guidance, Elsevier Editorial Manager submission requirements, and Manusights analysis of manuscripts that came through pre-submission review while targeting Biotechnology Advances. We did not test a private live Editorial Manager submission account for this page; the cover-letter and declaration guidance reflects public Elsevier materials and patterns observed in pre-submission review work. The IF 12.5, Q1, rank 5/177 figures are JCR 2024 values, consistent with our Biotechnology Advances impact factor page.

What a Biotechnology Advances cover letter does well: it gives review authors a one-page chance to convert a manuscript into an editorial argument, naming the synthesis position and the applied payoff before the file is routed.

Where the cover letter falls short: it cannot rescue a manuscript that is a literature survey rather than a critical synthesis, and it can create false confidence when the applied-fit claim still rests on a deployment path the body never demonstrates.